Relmada Therapeutics (RLMD) Change in Account Payables (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Change in Account Payables data on file, last reported at $1.8 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.8 million, up 161.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (up 152.66% YoY), and the FY2025 annual result was -$2.6 million, down 510.15% from the prior year.
• Change in Account Payables grew to $1.8 million in Q1 2026 per RLMD's latest filing, from $115842.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.2 million in Q2 2022 and troughed at -$3.5 million in Q3 2022.
• A 5-year average of -$88793.8 and a median of $96901.0 in 2025 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 300.38% in 2024 and fell as far as 335.04% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $1.2 million in 2022, then tumbled by 45.33% to $649257.0 in 2023, then surged by 174.93% to $1.8 million in 2024, then sank by 93.51% to $115842.0 in 2025, then surged by 1421.43% to $1.8 million in 2026.
• Business Quant data shows RLMD's Change in Account Payables at $1.8 million in Q1 2026, $115842.0 in Q4 2025, and $91191.0 in Q3 2025.